ROS1+ Efficacy

REFERENCES
  1. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Non-Small Cell Lung Cancer V.3.2020. © National Comprehensive Cancer Network, Inc. 2020. All rights reserved. Accessed February 12, 2020. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
  2. Shaw AT, Riely GJ, Bang YJ, et al. Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001 [published online April 13, 2019]. Ann Oncol. 2019;30(7):1121-1126. doi:10.1093/annonc/mdz131. Accessed June 28, 2019.
  3. Shaw AT, Ou SH, Bang YJ, et al. Crizotinib in ROS1-rearranged non–small-cell lung cancer. N Engl J Med. 2014;371(21):1963-1971.
  4. Protocol for: Shaw AT, Ou SH, Bang YJ, et al. Crizotinib in ROS1-rearranged non–small-cell lung cancer. N Engl J Med. 2014;371(21):1963-1971. https://www.nejm.org/doi/suppl/10.1056/NEJMoa1406766/suppl_file/nejmoa1406766_protocol.pdf. Accessed July 25, 2019.